A novel role for tissue factor pathway inhibitor-2 in the therapy of human esophageal carcinoma.

Abstract:

:Esophageal cancer is characterized by rapid clinical progression and poor prognosis, due to early-stage invasion of adjacent tissues and metastasis. Tissue factor pathway inhibitor-2 (TFPI-2) has been implicated as a metastasis-associated gene in many types of tumors. Here we describe the potential involvement of TFPI-2 in the development of esophageal carcinoma. Western blotting revealed that TFPI-2 was downregulated in 75% of esophageal carcinomas and in most esophageal carcinoma cell lines. Immunohistochemistry revealed that TFPI-2 was significantly downregulated in tumor tissues and in lymph node metastases. Experimental overexpression of TFPI-2 in KYSE450, KYSE510, YES2, and EC9706 cells significantly inhibited their invasive ability. Overexpression of TFPI-2 in EC9706 cells inhibited xenograft tumor growth and invasion into surrounding tissues, as well as reduced lung metastasis. Further studies demonstrated that recombinant TFPI-2 protein significantly inhibited the activity of matrix metalloproteinases and tumor-related angiogenesis. Parenteral treatment with recombinant TFPI-2 protein significantly suppressed xenograft growth and metastasis. Together, these data indicate that TFPI-2 inhibits tumor invasion and angiogenesis both in vitro and in vivo, and suggest a potentially important therapeutic role for recombinant TFPI-2 in the treatment of malignant esophageal carcinomas.

journal_name

Hum Gene Ther

journal_title

Human gene therapy

authors

Ran Y,Pan J,Hu H,Zhou Z,Sun L,Peng L,Yu L,Sun L,Liu J,Yang Z

doi

10.1089/hum.2008.129

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

41-9

issue

1

eissn

1043-0342

issn

1557-7422

journal_volume

20

pub_type

杂志文章
  • Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response.

    abstract::Gene therapy for heart diseases requires availability of an efficient vector for gene transfer into myocardium. Recombinant adenovirus expressing the Escherichia coli beta-galactosidase (beta-Gal) gene was shown to infect rat cardiocytes efficiently in vivo. However, a time course of gene expression showed that transg...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1995.6.10-1265

    authors: Gilgenkrantz H,Duboc D,Juillard V,Couton D,Pavirani A,Guillet JG,Briand P,Kahn A

    更新日期:1995-10-01 00:00:00

  • Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents.

    abstract::Immunoisolation of allogeneic cells within a membrane-bound device is a unique approach for gene therapy. We employed an immunoisolation device that protects allograft, but not xenograft, cells from destruction, to implant a human fibroblast line (MSU 1.2) in athymic rodents. Cells, transduced with the MFG-human facto...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.6-879

    authors: Brauker J,Frost GH,Dwarki V,Nijjar T,Chin R,Carr-Brendel V,Jasunas C,Hodgett D,Stone W,Cohen LK,Johnson RC

    更新日期:1998-04-10 00:00:00

  • Optimization of recombinant adeno-associated viral vectors for human beta-globin gene transfer and transgene expression.

    abstract::Therapeutic levels of expression of the beta-globin gene have been difficult to achieve with conventional retroviral vectors without the inclusion of DNase I-hypersensitive site (HS2, HS3, and HS4) enhancer elements. We generated recombinant adeno-associated viral (AAV) vectors carrying an antisickling human beta-glob...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2007.173

    authors: Maina N,Zhong L,Li X,Zhao W,Han Z,Bischof D,Aslanidi G,Zolotukhin S,Weigel-Van Aken KA,Rivers AE,Slayton WB,Yoder MC,Srivastava A

    更新日期:2008-04-01 00:00:00

  • Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation.

    abstract::Adenovirus type 5 (Ad5) is a commonly used vector for gene therapy, but its efficacy is limited by high seroprevalence and off-target hepatic and splenic sequestration. In order to circumvent these limitations, the use of vectors derived from rare species adenoviruses is appealing. The opportunity to retarget rare spe...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2014.016

    authors: Coughlan L,Uusi-Kerttula H,Ma J,Degg BP,Parker AL,Baker AH

    更新日期:2014-04-01 00:00:00

  • Mice with adenine phosphoribosyltransferase deficiency develop fatal 2,8-dihydroxyadenine lithiasis.

    abstract::Deficiencies in different steps of purine metabolism give rise to a number of human inherited disorders. Lesch-Nyhan syndrome is a severe neurological disorder, caused by a deficiency in the purine salvage enzyme hypoxanthine phosphoribosyltransferase (HPRT). HPRT-deficient mice have been generated, but have proved to...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1996.7.13-1491

    authors: Redhead NJ,Selfridge J,Wu CL,Melton DW

    更新日期:1996-08-20 00:00:00

  • Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.

    abstract::We reported total correction of blood coagulation plasma factor VIII (FVIII) activity, using adeno-associated virus serotype 8 (AAV8) vectors for liver-specific gene transfer in hemophilia A mice. We now show, irrespective of immunosuppression or route of administration, total long-term correction of hemophilia A mice...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2006.17.427

    authors: Sarkar R,Mucci M,Addya S,Tetreault R,Bellinger DA,Nichols TC,Kazazian HH Jr

    更新日期:2006-04-01 00:00:00

  • FUT-175, a synthetic inhibitor of the complement pathway, protects against the inactivation of infectious retroviruses by human serum.

    abstract::Serum-induced inactivation of retroviruses is the most critical limitation for in vivo gene transfer therapy. To solve this problem, we searched for reagents that protect retroviruses from inactivation. The effects of the protease inhibitors FOY-007 and FOY-305 and of an inhibitor of the complement pathway FUT-175, al...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.13-1575

    authors: Miyao Y,Ikenaka K,Kishima H,Tamura M,Nakamura K,Kurumi M,Hayakawa T,Shimizu K

    更新日期:1997-09-01 00:00:00

  • Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo.

    abstract::Replication-deficient adenoviruses are known to induce acute injury and inflammation of infected tissues, thus limiting their use for human gene therapy. However, molecular mechanisms triggering this response have not been fully defined. To characterize this response, chemokine expression was evaluated in DBA/2 mice f...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430349950018364

    authors: Muruve DA,Barnes MJ,Stillman IE,Libermann TA

    更新日期:1999-04-10 00:00:00

  • Retrovirus-mediated transfer of human alpha-galactosidase A gene to human CD34+ hematopoietic progenitor cells.

    abstract::Fabry disease, caused by a deficiency of lysosomal enzyme alpha-galactosidase A (alpha-gal A), is one of the inherited disorders potentially treatable by gene transfer to hematopoietic stem cells. In this study, a high-titer amphotropic retroviral producer cell line, MFG-alpha-gal A, was established. CD34+ cells from ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430349950016302

    authors: Takiyama N,Dunigan JT,Vallor MJ,Kase R,Sakuraba H,Barranger JA

    更新日期:1999-12-10 00:00:00

  • Production of recombinant adeno-associated virus vectors.

    abstract::Recombinant adeno-associated virus (rAAV) is a prototypical gene therapy vector characterized by excellent safety profiles, wide host range, and the ability to transduce differentiated cells. Numerous rAAV-based vectors providing efficient and sustained expression of transgenes in target tissues have been developed fo...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2005.16.551

    authors: Zolotukhin S

    更新日期:2005-05-01 00:00:00

  • A tissue-engineered stent for cell-based vascular gene transfer.

    abstract::Cell-based gene transfer using a stent platform would provide a significant advantage in terms of site-specific gene expression in the vasculature. The current study presents a novel stent design that allows stable in vivo transgene expression over a 4-week period in the vasculature. A mesh-stent coated with fibronect...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340252792567

    authors: Panetta CJ,Miyauchi K,Berry D,Simari RD,Holmes DR,Schwartz RS,Caplice NM

    更新日期:2002-02-10 00:00:00

  • Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles.

    abstract::Recombinant adeno-associated viral (AAV) vectors of serotypes 6, 8, and 9 were characterized as tools for gene delivery to dopaminergic neurons in the substantia nigra for future gene therapeutic applications in Parkinson's disease. While vectors of all three serotypes transduced nigral dopaminergic neurons with equal...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2012.174

    authors: Löw K,Aebischer P,Schneider BL

    更新日期:2013-06-01 00:00:00

  • Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer.

    abstract::Mucopolysaccharidosis type IIIA (MPSIIIA) is a rare lysosomal storage disorder caused by mutations in the sulfamidase gene. Accumulation of glycosaminoglycan (GAG) inside the lysosomes is associated with severe neurodegeneration as well as peripheral organ pathological changes leading to death of affected individuals ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2012.029

    authors: Ruzo A,Marcó S,García M,Villacampa P,Ribera A,Ayuso E,Maggioni L,Mingozzi F,Haurigot V,Bosch F

    更新日期:2012-12-01 00:00:00

  • Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial.

    abstract::Recombinant vectors based on adeno-associated virus serotype 8 (AAV8) have been successfully used in the clinic and hold great promise for liver-directed gene therapy. Preexisting immunity against AAV8 or the development of antibodies against the therapeutic transgene product might negatively affect the outcomes of ge...

    journal_title:Human gene therapy

    pub_type: 杂志文章,多中心研究

    doi:10.1089/hum.2014.109

    authors: Ferla R,Claudiani P,Savarese M,Kozarsky K,Parini R,Scarpa M,Donati MA,Sorge G,Hopwood JJ,Parenti G,Fecarotta S,Nigro V,Sivri HS,Van Der Ploeg A,Andria G,Brunetti-Pierri N,Auricchio A

    更新日期:2015-03-01 00:00:00

  • Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A.

    abstract::To develop a potential gene therapy strategy for the treatment of hemophilia A, we constructed several retroviral vectors expressing a B-domain-deleted factor VIII (FVIII) cDNA. We confirmed previous reports that when the FVIII cDNA is inserted into a retroviral vector, the vector mRNA is decreased resulting in signif...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1995.6.11-1363

    authors: Chuah MK,VandenDriessche T,Morgan RA

    更新日期:1995-11-01 00:00:00

  • Human fetal astrocytes as an ex vivo gene therapy vehicle for delivering biologically active nerve growth factor.

    abstract::The therapeutic use of neurotrophic factors for neurodegenerative diseases is promising, however, optimal methods for continuous delivery of these substances to the human central nervous system (CNS) remains problematic. One approach would be to graft genetically engineered human cells that continuously secrete high l...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.3-331

    authors: Lin Q,Cunningham LA,Epstein LG,Pechan PA,Short MP,Fleet C,Bohn MC

    更新日期:1997-02-10 00:00:00

  • Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.

    abstract::Malignant pleural mesothelioma (MPM) is a fatal disease with a median survival of less than 14 months. For the first time, a genetically engineered vaccinia virus is shown to produce efficient infection, replication, and oncolytic effect against MPM. GLV-1h68 is a replication-competent engineered vaccinia virus carryi...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2008.036

    authors: Kelly KJ,Woo Y,Brader P,Yu Z,Riedl C,Lin SF,Chen N,Yu YA,Rusch VW,Szalay AA,Fong Y

    更新日期:2008-08-01 00:00:00

  • Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells.

    abstract::Cell encapsulation offers a safe and manufacturable method for the systemic delivery of therapeutic proteins from genetically engineered cells. However, control of dose delivery remains a major issue with regard to clinical application. We generated populations of immortalized murine NIH 3T3 fibroblasts that secrete m...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430349950018823

    authors: Serguera C,Bohl D,Rolland E,Prevost P,Heard JM

    更新日期:1999-02-10 00:00:00

  • Addition of a single E2 binding site to the human papillomavirus (HPV) type 16 long control region enhances killing of HPV positive cells via HPV E2 protein-regulated herpes simplex virus type 1 thymidine kinase-mediated suicide gene therapy.

    abstract::Human papillomavirus type 16 (HPV16) is associated with the development of anogenital cancers and their precursor lesions, intraepithelial neoplasia. Treatment strategies against HPV-induced intraepithelial neoplasia are not HPV specific and mostly consist of physical removal or ablation of lesions. We had previously ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2009.115

    authors: Sharma R,Palefsky JM

    更新日期:2010-07-01 00:00:00

  • Cationic phosphonolipids as nonviral gene transfer agents in the lungs of mice.

    abstract::With the aim of developing new gene transfer tools for treating CF with gene therapy, we have synthesized a novel family of molecules named cationic phosphonolipids. The most efficient among them were selected by in vitro screening to compare their activities in vivo in mouse lungs. We used a reporter gene whose activ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.16-2309

    authors: Guillaume-Gable C,Floch V,Mercier B,Audrézet MP,Gobin E,Le Bolch G,Yaouanc JJ,Clément JC,des Abbayes H,Leroy JP,Morin V,Férec C

    更新日期:1998-11-01 00:00:00

  • Efficiency of high- and low-voltage pulse combinations for gene electrotransfer in muscle, liver, tumor, and skin.

    abstract::Gene electrotransfer is gaining momentum as an efficient methodology for nonviral gene transfer. In skeletal muscle, data suggest that electric pulses play two roles: structurally permeabilizing the muscle fibers and electrophoretically supporting the migration of DNA toward or across the permeabilized membrane. To in...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hgt.2008.060

    authors: André FM,Gehl J,Sersa G,Préat V,Hojman P,Eriksen J,Golzio M,Cemazar M,Pavselj N,Rols MP,Miklavcic D,Neumann E,Teissié J,Mir LM

    更新日期:2008-11-01 00:00:00

  • DNA-based vaccine against La Crosse virus: protective immune response mediated by neutralizing antibodies and CD4+ T cells.

    abstract::La Crosse virus (LACV)-mediated encephalitis is the most frequently reported arboviral disease in the United States, but to date no vaccine against this virus is available. We have established a new animal model, genetically targeted mice lacking a functional interferon type I receptor (IFNAR-1). These mice show an ag...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430349950017653

    authors: Schuh T,Schultz J,Moelling K,Pavlovic J

    更新日期:1999-07-01 00:00:00

  • Innate immunity to adenovirus.

    abstract::Human adenoviruses are the most widely used vectors in gene medicine, with applications ranging from oncolytic therapies to vaccinations, but adenovirus vectors are not without side effects. In addition, natural adenoviruses pose severe risks for immunocompromised people, yet infections are usually mild and self-limit...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2014.001

    authors: Hendrickx R,Stichling N,Koelen J,Kuryk L,Lipiec A,Greber UF

    更新日期:2014-04-01 00:00:00

  • Efficient transduction of mammalian cells by a recombinant baculovirus having the vesicular stomatitis virus G glycoprotein.

    abstract::Baculovirus vectors recently have been shown to be capable of efficient transduction of human hepatoma cells and primary hepatocytes in culture. This paper describes the generation of a novel recombinant baculovirus (VGZ3) in which the vesicular stomatitis virus glycoprotein G (VSV G) is present in the viral envelope....

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.17-2011

    authors: Barsoum J,Brown R,McKee M,Boyce FM

    更新日期:1997-11-20 00:00:00

  • Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse.

    abstract::The central nervous system (CNS) is a predominant site of involvement in several lysosomal storage diseases (LSDs); and for many patients, these diseases are diagnosed only after the onset of symptoms related to the progressive accumulation of macromolecules within lysosomes. The mucopolysaccharidosis type VII (MPS VI...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340050015707

    authors: Sferra TJ,Qu G,McNeely D,Rennard R,Clark KR,Lo WD,Johnson PR

    更新日期:2000-03-01 00:00:00

  • Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction.

    abstract::Despite improvements in drug and device therapy for heart failure, hospitalization rates and mortality have changed little in the past decade. Randomized clinical trials using gene transfer to improve function of the failing heart are the focus of this review. Four randomized clinical trials of gene transfer in heart ...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2016.166

    authors: Penny WF,Hammond HK

    更新日期:2017-05-01 00:00:00

  • Assessment of AAV Vector Tropisms for Mouse and Human Pluripotent Stem Cell-Derived RPE and Photoreceptor Cells.

    abstract::Adeno-associated viral vectors are showing great promise as gene therapy vectors for a wide range of retinal disorders. To date, evaluation of therapeutic approaches has depended almost exclusively on the use of animal models. With recent advances in human stem cell technology, stem cell-derived retina now offers the ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2018.027

    authors: Gonzalez-Cordero A,Goh D,Kruczek K,Naeem A,Fernando M,Kleine Holthaus SM,Takaaki M,Blackford SJI,Kloc M,Agundez L,Sampson RD,Borooah S,Ovando-Roche P,Mehat MS,West EL,Smith AJ,Pearson RA,Ali RR

    更新日期:2018-10-01 00:00:00

  • The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines.

    abstract::Human serum is known to inactivate many retroviruses, including murine leukemia viruses (MLV). Exposure of vectors based on MLV to human serum components would presumably decrease the efficiency of gene transfer in vivo. Human serum also lyses xenogeneic cells, which would affect the survival of retroviral vector pack...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1995.6.5-635

    authors: Russell DW,Berger MS,Miller AD

    更新日期:1995-05-01 00:00:00

  • ssDNA and the Argonautes: The Quest for the Next Golden Editor.

    abstract::Genome engineering has gone mainstream because of breakthroughs in defining and harnessing naturally occurring, customizable DNA recognition cursors (protein or RNA-guided). At present, most gene editing relies on these cursors to direct custom DNA endonucleases to a specific genomic sequence to induce a double-strand...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2016.071

    authors: Martínez-Gálvez G,Ata H,Campbell JM,Ekker SC

    更新日期:2016-06-01 00:00:00

  • Coexpression of cytidine deaminase and mutant dihydrofolate reductase by a bicistronic retroviral vector confers resistance to cytosine arabinoside and methotrexate.

    abstract::The transfer of a drug resistance gene into hematopoietic cells is an approach being investigated to overcome the problem of myelosuppression produced by anticancer drugs. Chemotherapeutic agents are often given in combination in order to increase their effectiveness. Consequently, there is an advantage in designing v...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.17-2537

    authors: Beauséjour CM,Le NL,Létourneau S,Cournoyer D,Momparler RL

    更新日期:1998-11-20 00:00:00